Why has non-addictive pain relief been such a hard drug development problem?

Why is it so hard to find a target that works in people?

The biggest hurdle is that many promising targets in the lab don't pan out in humans. A 2022 NIH workshop on non-addictive pain therapeutics noted that while there are 'plentiful novel targets for pain treatment, successful clinical validation is rare' [8]. The workshop proposed a roadmap requiring three types of evidence: human genetic or clinical data, in vitro assays, and in vivo animal models [8]. This rigorous bar means that many candidates that look good in early studies fail in expensive late-stage trials, discouraging investment.

One example of a target that has shown promise but also challenges is the voltage-gated sodium channel Nav1.7. A 2024 study engineered a spider venom peptide (ProTx2) to selectively block human Nav1.7, a well-known pain target, while avoiding a related channel (Nav1.4) that causes muscle side effects [6]. The mutant R13D maintained pain relief in mice and dramatically reduced muscle toxicity, but this is still preclinical work [6]. The difficulty of achieving such selectivity in a drug that is safe and effective in humans is a major reason non-addictive pain relief has been slow to emerge.

What does the best evidence look like, and how does it compare to typical results?

The strongest evidence here comes from a 2025 randomized phase 3 trial of VER-01, a standardized cannabis extract, versus opioids for chronic low back pain [1]. Over six months, VER-01 reduced pain by an average of 2.50 points on an 11-point scale, compared to 2.16 for opioids — a small but statistically significant difference [1]. Sleep improved by 2.52 points with VER-01 versus 2.07 with opioids [1]. Crucially, patients on VER-01 were four times less likely to develop constipation (relative risk 0.25) and three times less likely to need laxatives [1]. This is a best-case scenario: a large, well-designed trial showing a non-addictive option that is both safer and slightly more effective than opioids.

But most evidence is far less definitive. For example, a 2022 study of a non-drug topical patch (Kailo) reported a 61% reduction in pain severity over 30 days in an uncontrolled observational study, with no side effects [3]. While impressive, this lacks a blinded comparison and had a small control group that actually worsened [3]. Similarly, a 2022 study of 60-day peripheral nerve stimulation found that 30% of patients were early responders, but 32% never responded, and 7% lost their response over time [5]. These results highlight that even non-drug approaches work for some but not all, and that patient selection is critical.

The gap between best-case and typical evidence is also visible in opioid-sparing strategies. A 2025 review of hand surgery protocols found that non-opioid regimens work well for minor soft-tissue procedures but have 'limited data on bony and complex soft tissue procedures' and that 'multimodal approaches are not adequate' for some patients [7]. This means that even when alternatives exist, they don't cover all types of pain or all patients.

Can we avoid addiction by targeting pain at its source?

One promising strategy is to target pain receptors outside the brain and spinal cord, which could provide pain relief without the central nervous system effects that lead to addiction. A 2023 study in rats showed that loperamide, a drug that activates opioid receptors only in the periphery (it doesn't cross the blood-brain barrier), reduced chemotherapy-induced neuropathic pain without causing reward-seeking behavior (a sign of addiction potential) [4]. The study found that loperamide downregulated pain-related ion channels and inflammatory markers in the dorsal root ganglia and spinal cord [4]. This suggests that peripheral opioid receptors can be harnessed for pain relief without addiction risk.

However, this approach has limitations. The same study noted that loperamide is currently used only for diarrhea, and its use for pain would require new formulations to avoid gastrointestinal side effects [4]. Another peripheral approach is dexmedetomidine, an alpha-2 receptor agonist that has opioid-sparing effects in cancer pain, but a 2025 review cautioned that 'limited long-term safety data' exist and that 'high-quality, multicenter randomized controlled trials are needed' [2]. So while peripheral targeting is a promising avenue, it is still early days, and each candidate faces its own safety and efficacy hurdles.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2022 to 2025, 4 from 2024 or later, 4 in Q1 journals — selected as the most relevant from 10 studies that passed quality screening, drawn from 65 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions